Why is bioAffinity Technologies stock surging today?

bioAffinity Technologies stock surged +39.4% in pre-open trading after the company disclosed on Tuesday that its CyPath® Lung noninvasive diagnostic test is now positioned for post-curative surveillance, allowing physicians to monitor lung cancer recurrence in survivors and to deploy the test alongside routine imaging whenever new pulmonary nodules are identified. The announcement meaningfully widens the commercial scope of the company’s flagship product, which had previously been focused primarily on early-stage lung cancer detection in high-risk individuals.

A secondary but powerful amplifier behind today’s move is the stock’s extremely compressed float. bioAffinity implemented a 1-for-15 reverse stock split effective August 24, 2026, which left only a small number of shares in circulation; with limited supply, even moderate buying interest can produce outsized price swings, a dynamic that has been evident in BIAF’s trading since the consolidation took effect.

The broader market provided no meaningful tailwind to explain the move. The S&P 500 was essentially flat and the NASDAQ edged slightly lower on the session, underscoring that today’s rally is entirely a function of company-specific news rather than sector rotation or macro enthusiasm. Peers in the noninvasive diagnostics and lung health space did not report comparable catalysts.

Taken together, a commercially significant product expansion announcement — arriving while the stock sat near its 52-week low and carried a very thin float — created the conditions for an explosive pre-market reaction, as traders rapidly repriced the potential addressable market for CyPath® Lung upward.